Detalhe da pesquisa
1.
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
Ann Hematol
; 103(2): 427-436, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38012435
2.
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Br J Haematol
; 196(3): 559-565, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636033
3.
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.
Hematol Oncol
; 39(3): 401-408, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617659
4.
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
Ann Hematol
; 100(8): 2005-2014, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33388860
5.
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.
Acta Oncol
; 60(11): 1527-1533, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34499575
6.
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
Ann Hematol
; 99(7): 1525-1530, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32474619
7.
Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia.
Eur J Haematol
; 105(3): 286-291, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32365249
8.
Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.
Blood
; 130(5): 655-665, 2017 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28576876
9.
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.
Haematologica
; 104(8): 1589-1596, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30819917
10.
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
Hematol Oncol
; 37(3): 296-302, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30892724
11.
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.
Ann Hematol
; 98(10): 2329-2338, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31392461
12.
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.
Ann Hematol
; 97(9): 1577-1580, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29675611
13.
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.
Ann Hematol
; 97(1): 95-100, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28971265
14.
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation.
Blood
; 136(19): 2237-2240, 2020 11 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32518953
15.
Toxoplasmosis-Associated Hemophagocytic Lymphohistiocytosis in Allogeneic Transplantation.
J Clin Immunol
; 41(4): 843-846, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33515363
16.
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.
Am J Hematol
; 91(6): 617-22, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26971721
17.
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib.
Hematol Oncol
; 38(4): 607-610, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32602167
18.
Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.
Am J Hematol
; 95(10): E260-E263, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32557788
19.
Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study.
Am J Hematol
; 90(10): 910-4, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26178642
20.
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Cancer
; 120(7): 1002-9, 2014 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24382642